Applying a bit of logic, take a look at HOW MUCH MORE EFFECTIVE the combo treatment was as compared to the soc alone. The difference in the IMPROVEMENT can only be attributable to Brilacidan.
This is an excellent question. I am hoping for not only reduced time of infection, but also reduced times for those who had pneumonia and other complications prior to receiving Brilacidin in order to show the true value of the drug.
If we were to get 90% of patients COVID-free by day 15, and say, 100% of 30 patients who had pneumonia pre-injection became pneumonia-free by day 15 as well, then the data becomes stronger.
There is a control SOC group with 60 pts and a treatment group of 60 pts with the SOC +Brilacidin.
THE FDA and others felt the study without SOC treatment for both groups was unethical. The Phase 3 study may have direct comparisons.
ACTI-6, a large trial with multiple repurposed drugs, has begun. It is possible Brilacidin will be a part of a future similar study if the phase 2 study is possible.